All In Biotech

Drug Trial Radar · NCT04622345

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Allergic Conjunctivitis Using an Allergen Challenge Model

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

47

Actual

Start

Nov 21, 2020

Primary completion

May 22, 2021

Study completion Jun 28, 2021

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Conditions

  • Allergic Conjunctivitis

Interventions

  • VSJ-110Drug

    ophthalmic solution

  • PlaceboDrug

    ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Itching as Measured by Self-reported Numerical ScalesTime frame: 16 hours, 8 hours, and 15 minutes post-treatment
  2. Conjunctival Redness as Measured by Investigator Assessed Numerical ScalesTime frame: 16 hours, 8 hours, and 15 minutes post-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.